Population Genetics has developed a novel approach for the rapid identification of rare genetic variants in large populations of interest. This approach represents a significant advancement in the identification and utilisation of genetic biomarkers, which are fundamental to the development of personalised medicine.
The company’s unique proprietary technology, based on the work of one of our founders, Nobel Laureate Sydney Brenner, enables large-scale population genetics studies to be conducted, through the simultaneous analysis of regions of interest in thousands of individual genomes. This allows the identification of clinically and/or scientifically important genetic variations that cause predisposition to major diseases and varying responses to drug therapy. Population Genetics will provide its partners with an end to end capability, spanning study design, sample access, proprietary genomic technologies and bioinformatic correlations of genotype and phenotype – ultimately providing clinically relevant information rather than just sequence data.
Using the company’s unique technology, expertise and network of clinical collaborators, Population Genetics will become the world leader in applied population genetics, allowing its public and private sector partners to harness The Power of Populations™ for the benefit of the individual.